Cytomegalovirus (CMV) and Liver Transplantation
Cytomegalovirus (CMV) is a highly prevalent herpesvirus that establishes lifelong latency after initial infection. In individuals with intact immune systems, CMV usually causes no symptoms or only mild, self-limited illness. However, liver transplant recipients require long-term immunosuppressive therapy to prevent graft rejection, which significantly weakens antiviral immune defenses. As a result, CMV can reactivate or cause primary infection, leading to substantial morbidity after transplantation. CMV remains one of the most clinically important viral pathogens in liver transplantation due to its ability to cause both direct organ injury and broader immune dysregulation that affects patient survival. [1] [2]
CMV Overview
CMV belongs to the Herpesviridae family and is one of the most common human viral infections worldwide. Seroprevalence varies by geography and socioeconomic factors, ranging from approximately 40 percent in some populations to nearly universal exposure in others. Following primary infection, the virus enters a latent state within host cells and persists for life. In immunocompetent individuals, this latency is well controlled. In contrast, immunosuppression disrupts immune surveillance, allowing viral replication, tissue invasion, and systemic inflammatory effects that are particularly dangerous in liver transplant recipients. [1] [4]
Why CMV Matters After Liver Transplant
The clinical impact of CMV after liver transplantation is strongly influenced by donor and recipient CMV serostatus. The highest-risk scenario occurs when a CMV-positive donor provides an organ to a CMV-negative recipient, resulting in primary CMV infection without preexisting immunity. CMV infection in this setting has been associated with higher rates of graft dysfunction, acute rejection episodes, opportunistic bacterial and fungal infections, progressive fibrosis, and increased mortality. These risks make CMV prevention and early detection central priorities in post-transplant care. [4] [5]
Prevention, Monitoring, and Treatment
Modern CMV management in liver transplant recipients relies on structured prevention and surveillance strategies tailored to patient risk. Common approaches include universal antiviral prophylaxis, preemptive therapy guided by serial CMV DNA monitoring, or hybrid models combining both strategies. Valganciclovir and ganciclovir remain first-line antiviral agents and have significantly reduced early CMV disease rates. Regular viral load testing allows clinicians to identify viral replication early, initiate timely treatment, limit tissue-invasive disease, and reduce indirect CMV-related complications. [6] [7]